drugset
drugset / Trial / NCT07865676

Clinical Trial of CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection in the Treatment of Sarcopenia

NCT07865676 ↗

Phase 1/2 Recruiting 30 enrolled Guangzhou Cellgenes Biotechnology Co.,Ltd
Non-randomizedParallel-groupOpen-labelTreatment

Summary

1. To evaluate the safety and tolerability of CG-BM1 for the treatment of patients with Sarcopenia. 2. To observe the preliminary effectiveness of CG-BM1 in treating Sarcopenia patients.

Timeline

Start
2026-04-30
Primary completion
2029-06-30
Completion
2029-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject CG-BM1 Cell therapy 5e+07 cells Intravenous
Subject CG-BM1 Cell therapy 1e+08 cells Intravenous

Indications

muscular atrophy